This study is currently not recruiting participants.

A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases

Investigation of Bone Scan Responses in Patients

Not Recruiting
18 years - 100 years
Male
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).

Detailed description of study

The purpose of this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostatic Neoplasms
  • Age: 18 years - 100 years
  • Gender: Male

The purpose of this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA). This study investigates how patients respond to a specific type of bone scan, which uses a small amount of radioactive material to look for changes in the bones.

Participants will undergo bone scans at the start of the study and again at Week 24. These scans help researchers measure the area of bone lesions, which are abnormal areas that can be caused by various conditions. The study aims to see how these areas change over time.

  • Who can participate: The eligibility criteria for this study are not specified in the provided text. Please contact the study team for detailed eligibility requirements, including age criteria or key factors.
  • Study details: Participants will have bone scans at the beginning of the study and at Week 24 to measure changes in bone lesion areas.
Updated on 19 Feb 2024. Study ID: 1410410979 (16544)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team